CMV

Cost-effectiveness of Universal and Targeted Newborn Screening for Congenital Cytomegalovirus Infection

CMV Congenital CMV is common disease causing long-term morbidities, but is often unidentified at birth. This study assessed the cost effectiveness of universal screening compared to identification by newborn hearing test failure for congenital CMV in neonates >21 days of age. The study demonstrated that in highly resourced settings, universal screening for congenital CMV improves outcomes in neonates with congenital CMV.

Longer treatment for symptomatic congenital cytomegalovirus infection may have only modest long-term benefits.

VALGANCICLOVIR The long-term audiologic benefits of ganciclovir treatment for CMV infection are unclear. This randomized controlled trial evaluated the effectiveness of 6 week or 6 month valganciclovir therapy in improving audiologic outcomes. Although short-term outcomes were not different between groups, 6 month-treatment was associated with a slight improvement in hearing and neurodevelopmental outcome at 12 and 24 months. Thus, extended valganciclovir treatment may be appropriate for CMV infection.